Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, Japan.
Hum Reprod. 2010 Nov;25(11):2878-90. doi: 10.1093/humrep/deq240. Epub 2010 Sep 9.
We recently demonstrated the effect of gonadotrophin-releasing hormone agonist (GnRHa) on tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma. Here, we investigated expression of GnRH receptors (GnRHRs) and effect of GnRHa on the proliferation of cells derived from endometria and pathological lesions of women with these reproductive diseases.
Biopsy specimens were collected from lesions and corresponding endometria of 35 women with pelvic endometriosis, 45 women with ovarian endometrioma, 35 women with adenomyosis and 56 women with uterine myoma during laparoscopy or laparotomy. The gene and protein expressions of GnRHR in eutopic/ectopic cells and tissues were examined by reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry. The immunoreactivity of GnRHR in tissue was analysed by quantitative-histogram (Q-H) scores. The exogenous effect of GnRHa on cell proliferation was examined by 5-bromo-2-deoxyuridine incorporation assay. The Ki-67-immunoreactive cell proliferation index was analysed in biopsy specimens derived from GnRHa-treated and -non-treated women.
Types I and II GnRHRs mRNA and proteins were expressed in eutopic endometria and pathological lesions derived from women with endometriosis, adenomyosis and uterine myoma. GnRHR expression was the highest in the menstrual phase when compared with other phases of the menstrual cycle. Higher Q-H scores of GnRHR immunoreaction were found in blood-filled opaque red lesions than in other peritoneal lesions. Exogenous treatment with GnRHa significantly suppressed the proliferation of cells derived from respective endometria and pathological lesions when compared with GnRHa-non-treated cells.
Local tissue expression of GnRHR was detected in endometriosis, adenomyosis and uterine myoma. In addition to a hypo-estrogenic effect, a direct anti-proliferative effect of GnRHa may be involved in the regression of these reproductive diseases with consequent remission of clinical symptoms.
我们最近研究了促性腺激素释放激素激动剂(GnRHa)对子宫内膜异位症、子宫腺肌病和子宫肌瘤组织炎症、血管生成和细胞凋亡的影响。在此,我们研究了 GnRH 受体(GnRHR)的表达以及 GnRHa 对来自患有这些生殖疾病的女性的子宫内膜和病变组织的细胞增殖的影响。
通过腹腔镜或剖腹术收集 35 例盆腔子宫内膜异位症、45 例卵巢子宫内膜异位瘤、35 例子宫腺肌病和 56 例子宫肌瘤患者的病变和相应子宫内膜的活检标本。通过逆转录聚合酶链反应(RT-PCR)和免疫组织化学检测 GnRHR 在在位/异位细胞和组织中的基因和蛋白表达。通过定量直方图(Q-H)评分分析组织中 GnRHR 的免疫反应性。通过 5-溴-2-脱氧尿苷掺入试验检测 GnRHa 对细胞增殖的外源性影响。分析 GnRHa 治疗和非治疗妇女活检标本中的 Ki-67 免疫反应性细胞增殖指数。
I 型和 II 型 GnRHR mRNA 和蛋白在子宫内膜异位症、子宫腺肌病和子宫肌瘤患者的在位子宫内膜和病变中表达。与月经周期的其他阶段相比,GnRHR 表达在月经期最高。与其他腹膜病变相比,充满血液的不透明红色病变的 GnRHR 免疫反应 Q-H 评分较高。与 GnRHa 非治疗细胞相比,外源性 GnRHa 治疗显著抑制了来自各自子宫内膜和病变组织的细胞的增殖。
在子宫内膜异位症、子宫腺肌病和子宫肌瘤中检测到 GnRHR 的局部组织表达。除了低雌激素作用外,GnRHa 的直接抗增殖作用可能参与了这些生殖疾病的消退,从而缓解了临床症状。